Pheast Therapeutics

Pheast is a preclinical-stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system against cancer. Founded in 2020, Pheast is led by scientific experts in innate immunity and cancer immunotherapy, aiming to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, including women’s cancers such as ovarian and breast cancer.